ArticleOncoTargets and therapy2026
Multi-Omics Analysis Identifies Phosphoglucomutase 2 as a Potential Target to Alleviate Chemoradiotherapy Resistance in Cervical Cancer Cells.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the core treatment for cervical cancer, chemoradiotherapy efficacy is often limited by tumor heterogeneity-driven resistance. During chemoradiotherapy, the tumor microenvironment undergoes dynamic remodeling, with residual malignant cells evolving adaptively. However, the key regulatory genes driving therapeutic resistance remain elusive at single-cell resolution, which hinders the development of novel targeted therapies. Methods: Single-cell RNA sequencing (scRNA-seq) was performed on paired clinical samples from three cervical cancer patients before and after chemoradiotherapy to identify the cellular changes and the molecular mechanisms induced by chemoradiotherapy. Through integrated multi-omics data analysis, non-heterogeneity-dependent genes with prognostic value were identified. Furthermore, the biological function of the candidate gene in chemoradiotherapy-resistant HeLa cells was verified through in vitro functional experiments, including the detection of cell proliferation, migration and invasion abilities. Results: Chemoradiotherapy significantly reprogrammed the cellular composition of the tumor microenvironment (TME) in cervical cancer. Residual malignant cells showed activation of angiogenesis, epithelial-mesenchymal transition, stress-response, and cell-cycle programs. Eight heterogeneity-filtered prognostic genes were identified, and phosphoglucomutase 2 (PGM2) was prioritized because it was upregulated in cervical cancer, enriched in malignant cells, associated with poor prognosis, and supported by independent transcriptomic, spatial, and immunohistochemical evidence. PGM2 knockdown reduced proliferation, migration, and invasion in resistant HeLa cells. Conclusion: PGM2 may contribute to the malignant phenotype of chemoradiotherapy-resistant cervical cancer cells and represents a candidate biomarker and therapeutic target. Further validation in larger clinical cohorts and laboratory work is needed before clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.